Levoketoconazole Causes Dose-Related QT Interval Prolongation on ECG
Levoketoconazole causes dose-related QT interval prolongation, with the primary concern being QTc intervals exceeding 500 msec, which significantly increases the risk of life-threatening ventricular arrhythmias including torsades de pointes. 1
Key ECG Changes to Monitor
The specific ECG finding of concern is QT interval prolongation, measured as the corrected QT interval (QTc). According to the FDA label, the largest mean increase in QTc was 24 msec (upper confidence interval: 31 msec) following levoketoconazole 150-600 mg twice daily, and this effect is dose-dependent 1.
Critical Thresholds
- QTcF > 500 msec: Requires temporary discontinuation of levoketoconazole 1
- QTcF > 470 msec at baseline: Absolute contraindication to starting the drug 1
- Increase of ≥60 ms from baseline: High-risk threshold per general guidelines 2
Clinical Risk Stratification
Levoketoconazole is contraindicated in patients with:
- Baseline QTcF > 470 msec
- History of torsades de pointes, ventricular tachycardia, or ventricular fibrillation
- Long QT syndrome (including first-degree family history)
- Concurrent use of other QT-prolonging drugs 1
Monitoring Protocol
Before initiating levoketoconazole:
- Obtain baseline ECG to measure QTcF interval 1
- Check electrolytes (potassium, magnesium, calcium) 2
- Review all concurrent medications for QT-prolonging potential
During treatment:
- Regular ECG monitoring, particularly during dose titration 1
- Monitor electrolytes and renal function, especially if patient is on diuretics 2
- In clinical trials, 2.4% of patients experienced QTcF > 500 msec and 14% had clinically significant QT prolongation 1
Management of QT Prolongation
If QTcF exceeds 500 msec:
- Temporarily discontinue levoketoconazole immediately
- Correct contributing factors (hypokalemia, hypomagnesemia, other QT-prolonging drugs)
- May resume at lower dose once QTcF returns to ≤500 msec
- If QT prolongation recurs after restarting, permanently discontinue 1
Additional ECG Warning Signs
Beyond absolute QTc values, watch for these high-risk ECG patterns that suggest impending torsades de pointes 3:
- T-U wave distortion that becomes more exaggerated after pauses
- Visible T-wave alternans
- New-onset ventricular ectopy, couplets, or nonsustained polymorphic ventricular tachycardia initiated after a pause
- Bradycardia or rhythms with long pauses
Risk Factor Amplification
The risk of torsades de pointes is substantially higher when multiple risk factors coexist 2, 3:
- Female sex (higher baseline risk)
- Age ≥65 years
- Heart disease (heart failure, myocardial infarction)
- Electrolyte abnormalities (hypokalemia, hypomagnesemia, hypocalcemia)
- Concurrent QT-prolonging medications (avoid combination)
- Bradycardia or heart block
- Hepatic dysfunction (levoketoconazole is a CYP3A4 inhibitor)
Common Pitfall
The 2023 Canadian guidelines emphasize that antifungals are among the "anti's" to remember as QT-prolonging drugs 2. Levoketoconazole, derived from ketoconazole, carries this class effect. Do not assume that because a patient tolerates other medications well, they will tolerate levoketoconazole—the drug has specific dose-related QT effects documented in 10.7% of patients in clinical trials 4.
Practical Implementation
Use www.crediblemeds.org to check for drug interactions before prescribing 2. When levoketoconazole is essential despite QT concerns, avoid adding other QT-prolonging agents (macrolides, fluoroquinolones, certain antidepressants, antiemetics) and maintain strict electrolyte monitoring 2.